Research presented at ENDO 2024 found that environmental stress increased the likelihood of earlier alcohol, nicotine and cannabis use in females and traumatic events increased the likelihood in males.

Check out this recap of articles published on our sister sites during the past week.

In case you missed it, this week we had news about AI's role in promoting skin cancer awareness, the legalization of edible cannabis, expanding the role of the pharmacist, and more.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

Authors analyzed Section 804 of the Food, Drug, and Cosmetic Act (FDCA) allowing state-sponsored programs to bring Canadian drugs onto US soil.

According to a survey, 18.9% of respondents said that the person they knew who died of a drug overdose was a family member or close friend.

In an interview with Chris Schaffner, PharmD, owner of Schaffner Pharmacy and Apothecary Coffee in Sedro-Woolley, Washington, he discussed his unique pharmacy operation with the help of coffee shop revenue.

The SpeedySwab COVID + FLU A&B Self-Test from Watmind is intended for at-home and point-of-care use and can simultaneously detect COVID-19, influenza A, and influenza B in 15 minutes.

mRESVIA is the first mRNA vaccine approved for a disease other than COVID-19.

Check out a selection of our coverage from Mental Health Awareness Month.

As health care technology advances and cyberattack threats loom large, researchers aimed to assess the effect of ransomware attacks on US health systems.

Check out these can’t-miss dermatology stories published this month.

Researchers addressed the association between COVID-19 vaccination status and incidents of post-COVID condition.

Check out these important FDA updates from the month of May 2024.

Take a look back at the conference coverage you may have missed this month.

Roche's self-collection kit allows women to screen for cervical cancer at home, offering an alternative to a visit to a healthcare provider and promoting early detection of the disease.

The approval of Lisocabtagene maraleucel (Breyanzi; liso-cel) was based on data from the TRANSCEND-NHL-001 study, in which the therapy showed rapid and durable response rates.

The drug will be available in pharmacies during the second half of 2024.

Check out these featured Drug Topics expert interviews from May 2024.

Catch up on important continuous glucose monitoring (CGM) news from the month of May.

After 24 weeks of participation in an AI-driven lifestyle coaching program, 78% of all participants achieved a clinically meaningful SBP reduction of 5 mm Hg or greater.

Chris DesRochers, a pharmacy technician who works at a CVS in Wakefield, Rhode Island and is active in the recent organizing, discusses what motivated him and his coworkers to unionize.

Check out this list of our 10 most read stories from May 2024.

Patients with type 2 diabetes who used continuous glucose monitors combined with regular exercise had improved fasting glucose and 2 hours-postprandial glucose levels.

Eculizamab-aeeb is the 53rd FDA-approved biosimilar in the US.